NASDAQ:GILD Long-Term Investor Alert: Investigation of Gilead Sciences, Inc. Announced
An investigation for current investors in Gilead Sciences, Inc. (NASDAQ:GILD) shares over potential wrongdoing by certain officers and directors of Gilead Sciences, Inc. was announced and NASDAQ:GILD stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
San Diego, CA -- (SBWire) -- 05/06/2013 --An investigation on behalf of investors, who currently hold shares of Gilead Sciences, Inc. (NASDAQ:GILD), was announced concerning whether certain Gilead Sciences officers and directors possibly breached their fiduciary duties in connection with certain statements.
If you are a current long-term stockholder in shares of Gilead Sciences, Inc. (NASDAQ:GILD), you have certain options and you should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Gilead Sciences officers and directors breached their fiduciary duties and caused damage to the company and its shareholders by, among other things, failing to implement adequate internal controls.
Gilead Sciences, Inc. reported that its annual Total Revenue increased from over $8.38 billion in 2011 to over $9.39 billion in 2012. However, its respective Net Income declined from over $2.8 billion in 2011 to $2.59 billion in 2012.
On Apr. 29, 2013, Gilead Sciences, Inc. announced that the company has received Complete Response Letters from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for elvitegravir and cobicistat for use as part of HIV treatment regimens.
In its communications, FDA states that it cannot approve the applications in their current forms. Gilead Sciences, Inc. said that the letters state that during recent inspections, deficiencies in documentation and validation of certain quality testing procedures and methods were observed.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) closed on May 3, 2013, at $55.15 per share.
Those who purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Media Relations Contact
Trevor Allen
General Manager
Shareholders Foundation, Inc.
858-779-1554
http://www.ShareholdersFoundation.com
View this press release online at: http://rwire.com/247381